DART Filing · Auto-translated
📌 Key Filing Highlights
- Event Type: Investment in a related party via participation in a paid-in capital increase.
- Counterparty: Samsung Biologics Co., Ltd. (Affiliate).
- Investment Amount: 66.62 billion KRW (~$49.94 million USD based on 1334 KRW/USD).
- Key Date: Board approval on October 29, 2026; Scheduled payment date on November 17, 2026.
Filing Overview and Core Decision
On October 29, 2026, the Board of Directors of Samsung Electronics approved an investment in Samsung Biologics Co., Ltd., an affiliated company within the Samsung Group. This transaction constitutes a large-scale internal transaction with a related party, conducted in accordance with Article 26 of the Monopoly Regulation and Fair Trade Act. The investment is specifically for the purpose of participating in a paid-in capital increase (rights offering) by Samsung Biologics.
Detailed Filing Terms and Specifications
| Metric | Details |
|---|---|
| Counterparty | Samsung Biologics Co., Ltd. (Affiliate) |
| Investment Date | November 17, 2026 (Scheduled payment date) |
| Investment Asset | 567,503 shares of Samsung Biologics Common Stock |
| Investment Amount | 66.62 billion KRW (~$49.94 million USD based on 1334 KRW/USD) |
| Total Investment in Counterparty | 266.50 billion KRW (~$199.77 million USD based on 1334 KRW/USD) (Including current investment) |
| Board Approval Date | October 29, 2026 |
| Board Attendance | Independent Directors: 5 Present / 0 Absent; Auditors: Present |
Additional Regulatory Notes:
- The investment represents 100% of the shares allocated to existing shareholders.
- The investment amount is based on the proposed issuance price per share as of October 1, 2026, and is subject to change based on the final determined issuance price.
- The details of this transaction may be subject to change during the process of Samsung Biologics’ capital increase.
- Execution of the detailed matters regarding this transaction has been delegated to the CEO.
Operational Purpose and Company Rationale
The purpose of this investment is to participate in the paid-in capital increase (rights offering) of Samsung Biologics Co., Ltd. as an existing shareholder.